1 report

  • Deal Type
  • Company Overview

In early 2015, AstraZeneca will commence a Phase IIa study in patients with severe asthma, building on available clinical data from an initial Phase lla trial in a broad asthma population.

  • Asthma
  • Pharmaceutical
  • Australia
  • United Kingdom
  • Synairgen plc